MedTrace Logo

Ginkgo Biloba Extract in the Treatment of Schizophrenia

NCT05258123 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-02-28

No results posted yet for this study

Summary

We investigated the effects of Ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia

Conditions

Interventions

DRUG

Ginkgo Biloba Extract

Ginkgo biloba extract with 360mg was administered

DRUG

Placebo oral tablet

Placebo with nine tables was administered

Sponsors & Collaborators

  • Beijing HuiLongGuan Hospital

    lead OTHER

Principal Investigators

  • Xiang Y Zhang, M.D, Ph.D · Institute of Psychology, Chinese Academy of Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2018-06-12
Completion
2018-08-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258123 on ClinicalTrials.gov